Abiopharma

🔍 Aharon Gil (Director)

Company: Neuraxis, INC (NRXS)

Report Date: 2026-08-13

Detailed Transactions and Holdings:

• Acquired 2,226 shares of Common Stock (Direct)
  Date: 2026-07-29 | Code: A | equity_swap_involved: 0 | shares_owned_after: 36,128.00 | transaction_form_type: 4 | Footnotes: F1, F1
• Acquired 43,930 shares of Common Stock at $6.28 per share (Direct)
  Date: 2026-08-13 | Code: A | equity_swap_involved: 0 | shares_owned_after: 80,058.00 | transaction_form_type: 4 | Footnotes: F2, F2
• Acquired 40,068 shares of Common Stock (Direct)
  Date: 2026-07-29 | Code: A | equity_swap_involved: 0 | shares_owned_after: 548,123.00 | transaction_form_type: 4 | Footnotes: F1, F1, F3

Footnotes:

• F1: The number of shares of common stock issued as a dividend on the Series B Preferred Stock to Rosalind Master Fund L.P. and the Reporting Person were 40,068 and 2,226, respectively, and was determined by dividing the accrued and unpaid 8.5% cumulative dividends on the respective Series B Preferred Stock (from the investment date, through the applicable record or conversion date) by $2.38.
• F2: These shares of common stock were issued to the reporting person as compensation for services as independent director of the Issuer.
• F3: Each Reporting Persons disclaims beneficial ownership over the shares except to the extent of his or its respective pecuniary interest therein.